Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cartherics congratulates Rasa Islam on PhD success
By Karen Loudon / May 16, 2023
Cartherics is delighted to announce that Rasa Islam has successfully completed her PhD candidature. Rasa’s research thesis, titled, Re-engineering the...
Read More
Cartherics to present at the CIMT Annual Meeting in Germany
By Karen Loudon / May 2, 2023
Cartherics is pleased to announce that PhD Candidate, Van To, will be presenting at the Association for Cancer Immunotherapy’s 20th...
Read More
Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China
By Karen Loudon / April 28, 2023
Melbourne, Australia, 28 April 2023 – Cartherics Pty Ltd ("Cartherics"), a biotechnology company developing immune cell therapies for the treatment...
Read More
